Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Retained Earnings (2017 - 2025)

Inmune Bio's Retained Earnings history spans 9 years, with the latest figure at -$203.8 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 19569.21% year-over-year to -$203.8 million; the TTM value through Sep 2025 reached -$203.8 million, down 19569.21%, while the annual FY2024 figure was -$575000.0, 99.52% up from the prior year.
  • Retained Earnings for Q3 2025 was -$203.8 million at Inmune Bio, down from -$763000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $56000.0 in Q1 2022 and bottomed at -$203.8 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$1.1 million (2022), against an average of -$50.9 million.
  • The largest annual shift saw Retained Earnings crashed 579327.27% in 2021 before it surged 100.15% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$63.7 million in 2021, then skyrocketed by 98.9% to -$699000.0 in 2022, then crashed by 17210.44% to -$121.0 million in 2023, then skyrocketed by 99.52% to -$575000.0 in 2024, then tumbled by 35338.78% to -$203.8 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Retained Earnings are -$203.8 million (Q3 2025), -$763000.0 (Q2 2025), and -$172.8 million (Q1 2025).